

Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2016-2023

<https://marketpublishers.com/r/GA94100CD3AEN.html>

Date: September 2023

Pages: 700

Price: US\$ 3,995.00 (Single User License)

ID: GA94100CD3AEN

Abstracts

SUMMARY

Option and Evaluation Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2016 to 2023 Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter option and evaluation deals.

Fully revised and updated, the report provides details of option and evaluation deals from 2016 to 2023.

The report provides access to option and evaluation deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of option and evaluation deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by

companies and their partners.

The initial chapters of this report provide an orientation of option and evaluation dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in option and evaluation as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of option and evaluation deals.

Chapter 4 provides a review of the leading option and evaluation deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active option and evaluation dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of option and evaluation deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the option and evaluation deal.

The deal directory includes a comprehensive listing of all option and evaluation deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in option and evaluation dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about option and evaluation alliances.

Key benefits

Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

Understand deal trends since 2016

Browse option and evaluation deals

Benchmark analysis – identify market value of transactions

Financials terms

Directory of deals by company A-Z, therapy focus and technology type

Leading deals by value

Most active dealmakers

Identify assets and deal terms for each transaction

Access contract documents - insights into deal structures

Due diligence - assess suitability of your proposed deal terms for partner companies

Save hundreds of hours of research time

Report scope

Option and Evaluation Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the option and evaluation trends and structure of deals entered into by leading biopharma companies worldwide.

Option and Evaluation Deals in Pharmaceuticals and Biotechnology includes:

Trends in option and evaluation dealmaking in the biopharma industry

Overview of option and evaluation deal structure

Directory of option and evaluation deal records covering pharmaceutical and biotechnology

The leading option and evaluation deals by value

Most active option and evaluation dealmakers

The leading option and evaluation partnering resources

In Option and Evaluation Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

Company A-Z

Headline value

Therapeutic area

Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for option and evaluation deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the rights granted or optioned?

What rights are granted by the agreement?

What exclusivity is granted?

What is the payment structure for the deal?

How are sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are intellectual property rights handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

BENEFITS

Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

Understand deal trends since 2016

Browse option and evaluation deals

Benchmark analysis – identify market value of transactions

Financials terms

Directory of deals by company A-Z, therapy focus and technology type

Leading deals by value

Most active dealmakers

Identify assets and deal terms for each transaction

Access contract documents - insights into deal structures

Due diligence - assess suitability of your proposed deal terms for partner companies

Save hundreds of hours of research time

Contents

EXECUTIVE SUMMARY

CHAPTER 1 – INTRODUCTION

CHAPTER 2 – TRENDS IN OPTION AND EVALUATION DEALMAKING

- 2.1. Introduction
- 2.2. Definition of option and evaluation deal
- 2.3. Trends in option and evaluation deals since 2016
 - 2.3.1. Option and evaluation dealmaking by year, 2016-2023
 - 2.3.2. Option and evaluation dealmaking by phase of development, 2016-2023
 - 2.3.3. Option and evaluation dealmaking by industry sector, 2016-2023
 - 2.3.4. Option and evaluation dealmaking by therapy area, 2016-2023
 - 2.3.5. Option and evaluation dealmaking by technology type, 2016-2023
 - 2.3.6. Option and evaluation dealmaking by most active company, 2016-2023
- 2.4. Reasons for entering into option and evaluation partnering deals
- 2.5. The future of option and evaluation deals

CHAPTER 3 – OVERVIEW OF OPTION AND EVALUATION DEAL STRUCTURE

- 3.1. Introduction
- 3.2. Option and evaluation agreement structure

CHAPTER 4 – LEADING OPTION AND EVALUATION DEALS

- 4.1. Introduction
- 4.2. Top option and evaluation deals by value

CHAPTER 5 – TOP 25 MOST ACTIVE OPTION AND EVALUATION DEALMAKERS

- 5.1. Introduction
- 5.2. Top 25 most active option and evaluation dealmakers

CHAPTER 6 – OPTION AND EVALUATION DEALS INCLUDING CONTRACTS DIRECTORY

- 6.1. Introduction

6.2. Option and evaluation deals with contracts 2016-2023

Deal directory

Deal directory – option and evaluation dealmaking by companies A-Z

Deal directory – option and evaluation dealmaking by therapy area

Deal directory – option and evaluation dealmaking by technology type

About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from Current Partnering

TABLE OF FIGURES

Figure 1: Definition of option and evaluation

Figure 2: Trends in option and evaluation deal announcements, 2016-2023

Figure 3: Option and evaluation deals signed at each phase of development, 2016-2023

Figure 4: Option and evaluation deals by industry sector, 2016-2023

Figure 5: Option and evaluation deals by therapy area, 2016-2023

Figure 6: Option and evaluation deals by technology type, 2016-2023

Figure 7: Top 25 most active option and evaluation dealmakers, 2016-2023

Figure 8: Top option and evaluation deals by value, 2016-2023

Figure 9: Most active option and evaluation dealmakers, 2016-2023

I would like to order

Product name: Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2016-2023

Product link: <https://marketpublishers.com/r/GA94100CD3AEN.html>

Price: US\$ 3,995.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA94100CD3AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970